Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.


Download subscription form here



Latest News !

Victoria Innovation Minister Martin Pakula Talks Biotech

Dr Boreham's Crucible: Orthocell

Bionomics BNC210 Fails 2nd Phase II Trial (Agitation)

Biotech Daily Editorial: BNYM & Substantial Shareholder Notices

Ausbiotech: 'Threat To R&D Incentive Worries Sector'

Minister Karen Andrews Talks Biotech

Federal Election 2019: Policies & Comment

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Actinogen: 'Xanamem Fails Alzheimer's Endpoints'; Falls 71%

Paradigm Raising $78m On PPS Osteoarthritis Pain Trial Results

Federal Budget 2019 - Comment & Analysis

Oncosil Falls 87% On Pancreatic Cancer Radiation Doubts

2018 - The Year In Review



13-Year BDI-40 Up 339%, Big Caps Up 681% ASX200 Up 30%

12-Month BDI-40 Up 40%, Big Caps Up 13%, ASX200 Up 7%
NBI Down 1%

 12-Month Stars: Avita 792%, Genetic Signatures 268%, Paradigm 236%, Clinuvel 218%


July 1, 2019

June 30 marked a 13-year reckoning for the Biotech Daily Top 40 Index (BDI-40)*, up 220.8 percent on the raw collective market capitalization, and when adjusted for comings and goings like the ASX200, it was up 339.4 percent over the 13 years to June 30, 2019.
The ASX200 was up 30.4 percent over 13 years, but the collective market capitalization of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed a staggering 681.3 percent from just $17,156 million in 2006 to $134,039 million.
Four of the BDI-20 stocks have weathered the storms of 13 years and 10 of the BDI-40 have survived the distance.
Clinuvel is the 13-year best, up 2,484.6 percent from $65 million in 2006 to $1,680 million on June 30, 2019, with Mesoblast up 894.4 percent from $71 million to $706 million.
Polynovo joined the Billion Dollar Club in June, up 817.1 percent from the then Metabolic’s $111 million, to $1,018 million on June 30, followed by Starpharma up 310.6 percent to $518 million, Circadian-Opthea (288.4%), Neuren (202.6%) and Benitec (114.3%).
Others have not done so well. Pharmaxis has fallen 72.3 percent from $364 million to $101 million, Alterity-Prana improved just $1 million in 13 years to $25 million, Optiscan has fallen 43.4 percent to $27 million, with Antisense up 58.3 percent to $19 million.
Tenacious among the surviving demotions are several 2006 BDI-40 stocks including Acrux, Alchemia, Bionomics, Genetic Technologies, Living Cell, Phosphagenics (Avecho) and Phylogica.
For the year to June 30, 2019 the BDI-40 was up 40.3 percent, the Big Caps were up 12.8 percent, the ASX200 improved 6.8 percent and the NBI fell 0.7 percent.
The BDI-20 saw 16 companies up for the year, with just four falls. The Second 20 saw just five rises for the year and 15 falls.
Avita was the best of the BDI-20, up 792.0 percent from $88 million 12 months ago to $785 million, followed by Genetic Signatures (268.4%), Paradigm, (236.3%), Clinuvel (218.8%), Pro Medicus (213.8%), Polynovo (189.2%), Volpara (154.6%), Telix (110.1%), Nanosonics (77.9%), Opthea (57.5%), Cyclopharm (48.5%) and Starpharma (19.9%).
For the year to June 30, 2019, Neuren led the BDI-20 falls, down $184 million or 61.5 percent to $115 million, followed by Ellex (13.6%), Immutep (9.6%) and Cynata (2.3%).
For the month of June, 12 of the BDI-20 stocks were up, with five up by more than 10 percent and eight fell. The Second 20 had five up (four by more than 10 percent) and 13 fell, of which 11 fell by more than 10 percent.
On the Nasdaq, Vaxart (Biota) was unchanged at $15 million, Eyepoint (Psivida) was up 3.3 percent to $248 million, Queensland’s Protagonist was up 19.2 percent to $404 million and Israel’s Redhill with Australian assets was up 12.4 percent to $263 million. Cannabis Corner’s 18 companies slipped 2.7 percent despite the addition of two new companies.
Amplia and Resonance will replace Airxpanders and Reva in the Second 20.
* The BDI-40 is selected with the assistance of Lodge Partners analyst Marc Sinatra.
BDI-40 v S&P ASX200 Jun 30, 2006 to Jun 30, 2019 
3-Year Big Caps (Cochlear, CSL, Resmed) to Jun 30, 2019

BDI-40 ($m) v S&P ASX200 – Year to Jun 30, 2019 (current, raw data)



 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At June 30, 2019


* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Benitec, Cynata, Mesoblast
   Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: